Special Situations Advisory
Bespoke services for strategic business transformations in biotech
Special Situations Advisory
Bespoke services for strategic business transformations in biotech
Our Approach: The Risk-Sharing Partner
Counterpoint is a Business Transformation Complement Dedicated to Biotech
Biotechs navigate long-term capital-intensive cycles where value is rarely linear. Unwanted events such as a clinical failure, regulatory delay, market downturn, liquidity or governance crisis shift a company's trajectory.
Re-establishing value may require resolute portfolio prioritization, strengthened strategic partnerships, and a pragmatic focus on near-term milestones. Objective operational, strategic adjustments are vital to value creation and recovery.
As partners, we are complementary. We work collaboratively with the CEO and/or Board to deliver and execute tailored solutions through advisory or interim leadership roles.
Our services include:
- Financial risk exposure mitigation: managing and executing recapitalizations, debt restructurings, and equity re-financings
- Contract renegotiations and vendor realignments: securing key relationships for strategic pivots both near and long term
- In-and out-licensing monetization and asset sales: unlocking valuation, releasing liens, and/or cash
- Company (re-)formation and business development: rebuilding existing and new business activities toward growth
We leverage operational insight, disciplined finance and strategic expertise to drive transformative value in biotech.
Our Success: The Counterpoint Impact
Restart after a Failed M&A
Asset Sale to Release Liens
Stealth Biotech Redirection
Biotech with distressed board, substantial liabilities, dwindling cash reserves, and a skeleton management team, was successfully recapitalized by a new investor syndicate subset. We collaborated closely with the co-lead investors and Board to stabilize financials, renegotiate contracts, and restructure operations both pre and post refin
Biotech with distressed board, substantial liabilities, dwindling cash reserves, and a skeleton management team, was successfully recapitalized by a new investor syndicate subset. We collaborated closely with the co-lead investors and Board to stabilize financials, renegotiate contracts, and restructure operations both pre and post refinancing to rightsize into a rebuild
US, Cayman and China Operations and Investors
Stealth Biotech Redirection
Asset Sale to Release Liens
Stealth Biotech Redirection
Newly seeded stealth biotech faced unexpected upheaval within its Board and management. We created the company using institutional-level best practices as co-author of The Company Formation Playbook with a leading VC. Navigating alignment with CEO, we pivoted the organization through a redirection, and stabilized operations in the mids
Newly seeded stealth biotech faced unexpected upheaval within its Board and management. We created the company using institutional-level best practices as co-author of The Company Formation Playbook with a leading VC. Navigating alignment with CEO, we pivoted the organization through a redirection, and stabilized operations in the midst of fundraising efforts with potential new investors
Bi-coastal US Operations,
Boston-based Investor
Asset Sale to Release Liens
Asset Sale to Release Liens
Asset Sale to Release Liens
Wind-down of biotech with extremely limited cash (13-week cashflow forecast for CEO retention and essentials), we collaborated and executed a full loan payoff and lien release from an IP/Asset sale with a single suitor. We negotiated, restructured and repriced significant high-risk debt assets to include a large syndicated loan
Bi-coastal US Operations, Lenders and Investors